Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases.

Profile

Social Media

Sirtris Pharmaceuticals Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Christoph Westphal

Chief Operating Officer

Garen Bohlin

Vice President

Peter Elliott

VP - Finance

Paul Brannelly

VP - R & D

Michael Jirousek

Browse more venture capital transactions:

Prev: 3/31/2005: IntelliDx venture capital transaction
Next: 3/31/2005: Biolex venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary